Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.64 |
| ▸ | RAB9A | P51151 | 6/20 | 0.64 |
| ▸ | TP53 | P04637 | 3/20 | 0.64 |
| ▸ | NPC1 | O15118 | 3/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22627288 | 0.86 | L3MBTL1 (0.74) | LMNASMN1; SMN2RAB9ATP53NPC1 | |
| SCHEMBL5379370 | 0.86 | TSHR (0.65) | LMNAMAPK1SMN1; SMN2RAB9ATP53 | |
| SCHEMBL15294614 | 0.86 | SMN1; SMN2 (0.86) | LMNAMAPK1SMN1; SMN2RAB9ATP53 | |
| SCHEMBL1520758 | 0.85 | ALDH1A1 (0.76) | LMNAMAPK1SMN1; SMN2RAB9ATP53 | |
| SCHEMBL18148387 | 0.85 | RAB9A (0.64) | LMNAMAPK1SMN1; SMN2RAB9ATP53 | |
| SCHEMBL31189925 | 0.84 | SMN1; SMN2 (0.65) | LMNAMAPK1SMN1; SMN2RAB9ATP53 | |
| SCHEMBL1520364 | 0.83 | POLB (0.69) | LMNAMAPK1SMN1; SMN2RAB9ATP53 | |
| SCHEMBL29205484 | 0.82 | SMN1; SMN2 (0.62) | LMNAMAPK1SMN1; SMN2RAB9ATP53 | |
| SCHEMBL12776001 | 0.82 | KMT2A (0.68) | LMNAMAPK1SMN1; SMN2RAB9ATP53 | |
| SCHEMBL30281572 | 0.82 | SMN1; SMN2 (0.62) | LMNAMAPK1SMN1; SMN2RAB9ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1979343-A2 | BICYCLIC HETEROARYL COMPOUNDS AS PDE10 INHIBITORS | Pfizer Products Inc. (US) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007077490-A2 | BICYCLIC HETEROARYL COMPOUNDS AS PDE10 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2007-07-12 | — | — | WO | disclosed |
| US-20070155779-A1 | BICYCLIC HETEROARYL COMPOUNDS AS PDE10 INHIBITORS | PFIZER INC | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155779-A1 | BICYCLIC HETEROARYL COMPOUNDS AS PDE10 INHIBITORS | PDE12, PDE10A, PDE7A | LMNA 3635/4885MAPK1 2052/4885SMN1; SMN2 1443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.